In one study, BAY-598 reversed cisplatin resistance in NSCLC as it significantly decreased cell migration, tumour sphere number and induced apoptosis of cisplatin-treated lung cancer cells through the upregulation of p53 target genes including cyclin-dependent kinase inhibitor 1 (p21), Bcl-2-associated protein x (Bax) and Growth arrest and DNA damage-inducible protein GADD45 (GADD45) (Shang and Wei, 2019). This evidence concerns the gene TP53 and non-small cell lung carcinoma.